Impact of the IRA on Biotech Builders
Experts from the innovator, investor, and health plan communities provide analysis for biotech leaders on the impacts of new IRA legislation -- and propose fixes to make it better for patients and innovators.
Lesson 1: What the IRA will do to biotech
Lesson 2: The good, the bad, and the ugly
Lesson 3: The IRA's effect on valuations, and why GCEAs are a company's best defense
Lesson 4: Getting 9 to 13
Lesson 5: Why drug companies can't just charge more
Lesson 6: "I thought this was only about medicare"... NOPE